John M Burke
John M Burke
President and CEO, Applied BioMath
Verified email at - Homepage
Cited by
Cited by
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
SL Spencer, S Gaudet, JG Albeck, JM Burke, PK Sorger
Nature 459 (7245), 428-432, 2009
Physicochemical modelling of cell signalling pathways
BB Aldridge, JM Burke, DA Lauffenburger, PK Sorger
Nature cell biology 8 (11), 1195-1203, 2006
Quantitative analysis of pathways controlling extrinsic apoptosis in single cells
JG Albeck, JM Burke, BB Aldridge, M Zhang, DA Lauffenburger, ...
Molecular cell 30 (1), 11-25, 2008
Modeling a snap-action, variable-delay switch controlling extrinsic cell death
JG Albeck, JM Burke, SL Spencer, DA Lauffenburger, PK Sorger
PLoS biology 6 (12), e299, 2008
Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks
DC Kirouac, J Saez-Rodriguez, J Swantek, JM Burke, DA Lauffenburger, ...
BMC systems biology 6, 1-17, 2012
Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation
DS Jones, AP Jenney, JL Swantek, JM Burke, DA Lauffenburger, ...
Nature chemical biology 13 (1), 38-45, 2017
Systematic calibration of a cell signaling network model
KA Kim, SL Spencer, JG Albeck, JM Burke, PK Sorger, S Gaudet, DH Kim
BMC bioinformatics 11, 1-14, 2010
Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: scientific rationale and review
CD Barrett, HB Moore, EE Moore, RC McIntyre, PK Moore, J Burke, F Hua, ...
Research and Practice in Thrombosis and Haemostasis 4 (4), 524-531, 2020
Quantitative systems pharmacology model of hUGT1A1‐modRNA encoding for the UGT1A1 enzyme to treat Crigler‐Najjar syndrome type 1
JF Apgar, JP Tang, P Singh, N Balasubramanian, J Burke, MR Hodges, ...
CPT: pharmacometrics & systems pharmacology 7 (6), 404-412, 2018
Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase …
BS Hendriks, J Cook, JM Burke, JM Beusmans, DA Lauffenburger, ...
IEE Proceedings-Systems Biology 153 (1), 22-33, 2006
Quantitative systems toxicology
P Bloomingdale, C Housand, JF Apgar, BL Millard, DE Mager, JM Burke, ...
Current opinion in toxicology 4, 79-87, 2017
Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.
HA Burris, MK Callahan, AW Tolcher, S Kummar, GS Falchook, ...
Journal of Clinical Oncology 35 (15_suppl), 3033-3033, 2017
Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease
K Madrasi, R Das, H Mohmmadabdul, L Lin, BT Hyman, ...
Alzheimer's & Dementia 17 (9), 1487-1498, 2021
Quantitative systems pharmacology model of a masked, tumor‐activated antibody
M Stroh, J Sagert, JM Burke, JF Apgar, L Lin, BL Millard, WM Kavanaugh
CPT: Pharmacometrics & Systems Pharmacology 8 (9), 676-684, 2019
Model‐informed drug development of the masked Anti‑PD‑L1 antibody CX‐072
M Stroh, M Green, BL Millard, JF Apgar, JM Burke, W Garner, H Lu, ...
Clinical Pharmacology & Therapeutics 109 (2), 383-393, 2021
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
L Lin, F Hua, C Salinas, C Young, T Bussiere, JF Apgar, JM Burke, ...
CPT: pharmacometrics & systems pharmacology 11 (3), 362-372, 2022
Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer
H Sayama, D Marcantonio, T Nagashima, M Shimazaki, T Minematsu, ...
CPT: Pharmacometrics & Systems Pharmacology 10 (8), 864-877, 2021
A quantitative systems pharmacology model of colonic motility with applications in drug development
R Das, L Wille, L Zhang, C Chen, W Winchester, J Selimkhanov, ...
Journal of Pharmacokinetics and Pharmacodynamics 46 (5), 485-498, 2019
An introduction to the regulatory and nonclinical aspects of the nonclinical development of antibody drug conjugates
JA Lansita, JM Burke, JF Apgar, B Mounho-Zamora
Pharmaceutical research 32 (11), 3584-3592, 2015
A systems pharmacology model for gene therapy in sickle cell disease
B Zheng, L Wille, K Peppel, D Hagen, A Matteson, J Ahlers, J Schaff, ...
CPT: Pharmacometrics & Systems Pharmacology 10 (7), 696-708, 2021
The system can't perform the operation now. Try again later.
Articles 1–20